Compare Digital Realty Trust, Inc. (DLR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Digital Realty Trust, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Digital Realty Trust, Inc. trades at $176.26 (market cap $65.32B), while State Street SPDR S&P Biotech ETF trades at $149.8 (market cap $10.11B). The key difference: Digital Realty Trust, Inc. is far larger — about 6.5× State Street SPDR S&P Biotech ETF's market cap, and Digital Realty Trust, Inc. pays a 2.77% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Digital Realty Trust, Inc. for 94 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| DLR | XBI | |
|---|---|---|
Market Cap | $65.32B | $10.11B |
Volume | 2,563,950 | 12,903,266 |
Sector | Real Estate | Broad Market / Factor |
52-Week High | $203.91 | $169.55 |
52-Week Low | $147.93 | $104.99 |
Typical Hold Time | 94 Days | 37 Days |
Enterprise Value | $84.03B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DLR trades at $180.47, down 2.26% today, with a bearish technical signal. The stock shows strong fundamentals: revenue grew to $6.11B in 2025, net income margin improved to 21.4%, and Q2 2026 EPS beat expectations. Analysts are overwhelmingly bullish with a $222.35 consensus target. Recent news highlights AI infrastructure expansion, including a partnership with Blackfuel and a new cable landing station in Los Angeles, driving positive sentiment.
Outlook is positive due to robust AI-driven demand and record leasing activity, but risks include high valuation (P/E 88.03) and significant capital expenditures. Net cash flow turned negative in 2025, and debt levels remain elevated. The stock offers growth potential from the AI boom, yet investors should weigh execution risks and macroeconomic sensitivity.
XBI trades at $150.23, down 0.44% on the day, with bearish technical signals dominating. The ETF faces resistance near $152-154 while finding support at $147-149 levels. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech sector optimism from M&A activity and cancer vaccine breakthroughs. The fund's 0.35% expense ratio compares unfavorably to broader healthcare ETFs but offers targeted biotech exposure.
Outlook remains mixed with technical weakness offset by sector catalysts. The biotech focus provides growth potential but carries higher volatility than diversified healthcare alternatives. Key risks include sector-specific regulatory pressures and the fund's expense structure, while opportunities exist from ongoing pharmaceutical innovation and capital market improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Digital Realty Trust, Inc.
Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.
Read more on DLR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
